PER57 Antibody

What is ERp57/PDIA3 and why is it significant in research?

ERp57 (Endoplasmic reticulum resident protein 57), also known as Protein disulfide-isomerase A3 (PDIA3), is a 57-60 kDa member of the protein disulfide isomerase family. This protein plays crucial roles in endoplasmic reticulum quality control of newly synthesized glycoproteins, major histocompatibility complex class I assembly, and gene expression regulation. ERp57 has significant research importance due to its implicated role in human pathologies including cancer and Alzheimer's disease . Antibodies targeting ERp57 are valuable tools for investigating these cellular processes and disease mechanisms. The high sequence similarity between human and mouse ERp57 (92% amino acid sequence identity within amino acids 107-366) makes these antibodies useful across multiple model systems .

How is the specificity of ERp57/PDIA3 antibodies validated?

Validation of ERp57/PDIA3 antibodies typically involves multiple complementary approaches to confirm specificity. Researchers employ Western blotting across different cell lines (such as HeLa human cervical epithelial carcinoma, HEK293 human embryonic kidney, and Hepa 1-6 mouse hepatoma cell lines) to verify that the antibody recognizes a protein of the expected molecular weight . Immunocytochemistry on fixed cells and immunohistochemistry on tissue sections provide further validation of specificity by demonstrating the expected subcellular localization pattern. Cross-reactivity with other PDI family members should be tested, particularly because ERp57 shares structural similarities with other family members. For conclusive validation, knockdown or knockout of ERp57 should eliminate or significantly reduce the antibody signal in experimental systems.

What are the primary applications of ERp57/PDIA3 antibodies in molecular biology?

ERp57/PDIA3 antibodies have demonstrated utility in multiple molecular biology applications. Primary validated applications include:

• Immunocytochemistry: Used on fixed cell lines like HeLa to visualize subcellular localization

• Immunohistochemistry: Effective on paraffin-embedded tissue sections, including human liver samples

• Western Blot: Validated across multiple human and mouse cell lines for protein expression analysis

• Protein-protein interaction studies: Investigating ERp57's role in multi-protein complexes

• Extracellular matrix studies: Research has shown that knockdown of ERp57 or antibody-targeted inhibition of the secreted form significantly impairs secretion and accumulation of extracellular matrix components

These applications enable researchers to investigate both the intracellular functions of ERp57 in protein folding and its potential extracellular roles in various physiological and pathological contexts.

How should researchers optimize antibody concentrations for different applications?

Optimization of ERp57/PDIA3 antibody concentrations requires systematic titration experiments specific to each application. For Western blotting, begin with a concentration range of 0.1-1.0 μg/mL and assess signal-to-noise ratios. For immunohistochemistry and immunocytochemistry, initial dilutions of 1:100 to 1:500 are recommended, followed by fine-tuning based on signal intensity and background levels. The optimization process should include appropriate positive controls (tissues or cells known to express ERp57) and negative controls (isotype controls or blocking peptides). Researchers should be aware that different sample preparation methods (fixation protocols, antigen retrieval techniques) may significantly affect antibody performance, necessitating application-specific optimization. Documentation of optimization parameters is essential for experimental reproducibility.

What sample preparation techniques yield optimal results with ERp57/PDIA3 antibodies?

Sample preparation significantly impacts ERp57/PDIA3 antibody performance across different applications. For Western blotting, protein extraction should preserve native protein conformation, typically using non-denaturing lysis buffers containing appropriate protease inhibitors. For immunohistochemistry, immersion fixation of paraffin-embedded tissue sections has been validated , with attention to antigen retrieval methods (heat-induced or enzymatic) to expose epitopes that may be masked during fixation. For immunocytochemistry, immersion fixation of cultured cells like HeLa has proven effective . When analyzing ERp57's role in extracellular matrix formation, careful extraction and preservation of extracellular components is essential. Researchers should consider that ERp57's localization spans multiple cellular compartments (predominantly ER but also secreted forms), requiring preparation techniques that maintain these distinct pools.

How can researchers differentiate between ERp57/PDIA3 and other PDI family members?

Differentiating between ERp57/PDIA3 and other PDI family members presents a significant challenge due to their structural similarities. Researchers should employ multiple approaches:

• Epitope selection: Choose antibodies targeting unique regions of ERp57 not conserved in other PDI family members. The region between amino acids 107-366 contains sequences with sufficient divergence from other PDI proteins .

• Western blot analysis: Utilize the subtle molecular weight differences between PDI family members (ERp57 at 57-60 kDa versus others) on high-resolution gels.

• Knockdown validation: Perform siRNA knockdown of ERp57 to confirm antibody specificity by showing reduced signal.

• Recombinant protein controls: Include purified recombinant proteins of multiple PDI family members as controls to assess cross-reactivity.

• Immunoprecipitation followed by mass spectrometry: For definitive identification, use the antibody for immunoprecipitation followed by mass spectrometry analysis of the precipitated proteins.

This multi-layered approach ensures reliable discrimination between closely related PDI family members in experimental systems.

How can cryoEM techniques be applied to study ERp57/PDIA3 antibody interactions?

Cryo-electron microscopy (cryoEM) offers powerful capabilities for studying ERp57/PDIA3 antibody interactions at near-atomic resolution. This technique enables visualization of antibody-antigen complexes without the need for crystallization. For ERp57/PDIA3 antibody studies, researchers can adapt protocols similar to those used in other antibody-protein complex analyses . The process typically involves:

• Formation of antibody-ERp57 complexes by incubating purified ERp57/PDIA3 with Fab fragments of the antibody (15 μg of each) for approximately 1 hour at room temperature.

• Purification of the complex via size-exclusion chromatography using appropriate buffer conditions (e.g., TBS at pH 7.4).

• Application of the purified complex to carbon-coated copper grids at an optimal concentration (approximately 20 μg/ml) followed by negative staining with uranyl formate (2% w/v) for initial characterization.

• Data collection using transmission electron microscopy (e.g., Tecnai F20) with appropriate parameters (200 keV, ~1.77 Å per pixel, 62,000× magnification).

• Image processing and 3D reconstruction using software packages like Relion 3.0, followed by visualization in programs such as UCSF Chimera .

This approach can reveal the precise epitope binding and structural changes induced by antibody recognition, providing insights unavailable through other techniques.

What high-throughput methods can characterize ERp57/PDIA3 antibody specificity across the proteome?

High-throughput characterization of ERp57/PDIA3 antibody specificity can be accomplished through several advanced proteomics approaches:

• Protein microarrays: Similar to those used in autoantibody studies , protein microarrays containing thousands of human proteins can identify potential cross-reactivity of ERp57/PDIA3 antibodies.

• Immunoprecipitation-mass spectrometry (IP-MS): This approach involves immunoprecipitating proteins from cellular lysates using the ERp57/PDIA3 antibody, followed by mass spectrometry identification of all captured proteins, revealing both intended targets and off-target interactions.

• Phage display libraries: Screening antibodies against phage-displayed peptide libraries can map precise epitopes and identify potential cross-reactive sequences.

• Next-generation sequencing coupled analysis: Following techniques similar to those used for VH-VL pairing analysis , researchers can analyze antibody binding preferences across large libraries of protein variants.

• High-content imaging: Automated microscopy of cells treated with siRNA libraries targeting various proteins can identify which knockdowns affect antibody staining patterns.

These approaches provide comprehensive assessment of antibody specificity beyond traditional Western blot or ELISA methods, critical for validating antibodies used in complex experimental systems.

How can researchers explore the antibody repertoire against ERp57/PDIA3 after natural infection or immunization?

Investigating the antibody repertoire against ERp57/PDIA3 requires sophisticated immune repertoire analysis techniques. Researchers can adapt methods like those described for VH-VL repertoire analysis to study anti-ERp57 responses:

• Single-cell analysis: Using emulsion-based technologies, individual B cells from immunized subjects can be isolated and their antibody heavy and light chain sequences determined with >97% pairing precision .

• Next-generation sequencing (NGS): The entire B cell repertoire can be sequenced to identify clonal families of antibodies targeting ERp57/PDIA3.

• Functional screening: Identified sequences can be expressed as recombinant antibodies and screened for binding to different epitopes of ERp57/PDIA3.

• Epitope mapping: Advanced techniques like hydrogen-deuterium exchange mass spectrometry or cryo-EM can map exactly which regions of ERp57/PDIA3 are recognized by different antibody clones.

• Longitudinal analysis: Tracking the evolution of anti-ERp57 antibodies over time after immunization can reveal how affinity maturation progresses for this antigen.

This comprehensive approach provides insights into both the breadth and specificity of immune responses to ERp57/PDIA3, potentially informing therapeutic antibody development or understanding autoimmune responses targeting this protein.

How are ERp57/PDIA3 antibodies utilized in cancer research?

ERp57/PDIA3 antibodies serve as crucial tools in cancer research due to the protein's altered expression and function in various malignancies. Researchers employ these antibodies in multiple cancer-focused applications:

• Expression profiling: Immunohistochemistry using ERp57/PDIA3 antibodies on tissue microarrays allows quantification of expression levels across different cancer types and correlation with clinical outcomes.

• Cellular localization studies: While ERp57 is predominantly an ER protein, cancer cells may show altered subcellular distribution. Immunofluorescence with ERp57 antibodies can reveal these pathological localization patterns.

• Functional studies: Neutralizing antibodies against extracellular ERp57 can help elucidate its role in cancer cell invasion and metastasis, as knockdown studies have shown impaired extracellular matrix secretion with reduced ERp57 .

• Biomarker validation: ERp57/PDIA3 antibodies facilitate the validation of this protein as a potential diagnostic or prognostic biomarker in various cancer types.

• Therapeutic target assessment: As ERp57 may represent a therapeutic target, antibodies help validate target engagement in drug development pipelines.

These applications contribute to understanding ERp57's complex roles in cancer biology and potentially identifying new therapeutic strategies.

What role does ERp57/PDIA3 play in neurodegenerative diseases and how can antibodies help investigate this?

ERp57/PDIA3 has been implicated in neurodegenerative conditions, particularly Alzheimer's disease . Antibodies against ERp57 provide valuable research tools to investigate several aspects of this connection:

• Protein-protein interactions: ERp57/PDIA3 antibodies can help identify binding partners in the brain through co-immunoprecipitation, revealing how ERp57 interacts with disease-relevant proteins like amyloid precursor protein or tau.

• Expression changes: Immunohistochemistry with ERp57 antibodies on brain tissue sections from patients and controls can quantify expression changes in different brain regions and disease stages.

• ER stress response: Since ERp57 functions in protein folding, antibodies can help monitor ER stress responses in neuronal models of neurodegeneration.

• Post-translational modifications: Antibodies recognizing specific modified forms of ERp57 can reveal how post-translational modifications affect its function in disease states.

• Animal model validation: ERp57/PDIA3 antibodies allow researchers to confirm that animal models of neurodegeneration recapitulate the ERp57-related changes seen in human disease.

These investigations may reveal whether ERp57 represents a potential therapeutic target or biomarker for neurodegenerative conditions, particularly given its established role in protein quality control.

How can researchers investigate the potential role of ERp57/PDIA3 as an autoantigen?

Investigating ERp57/PDIA3 as a potential autoantigen requires specialized techniques to detect and characterize autoantibodies. Researchers can adapt methods from autoantibody studies to explore this possibility:

• Protein microarray screening: Using purified ERp57/PDIA3 on protein microarrays to screen sera from patients with suspected autoimmune conditions versus healthy controls.

• ELISA development: Establishing sensitive enzyme-linked immunosorbent assays using recombinant ERp57/PDIA3 to quantify autoantibody levels in patient populations.

• Epitope mapping: Determining which regions of ERp57/PDIA3 are recognized by autoantibodies through peptide arrays or hydrogen-deuterium exchange mass spectrometry.

• Cross-reactivity analysis: Investigating whether autoantibodies to ERp57/PDIA3 cross-react with pathogen-derived proteins, suggesting molecular mimicry as a potential mechanism .

• Functional consequences: Assessing whether autoantibodies to ERp57/PDIA3 affect its biological functions through in vitro enzymatic assays or cellular studies.

This approach may reveal whether ERp57/PDIA3 belongs among the 77 common autoantigens identified in healthy individuals or represents a disease-specific autoantigen, contributing to our understanding of autoimmunity.

How can researchers address inconsistent staining patterns with ERp57/PDIA3 antibodies?

Inconsistent staining patterns with ERp57/PDIA3 antibodies may stem from several technical factors. Researchers should systematically address these issues through:

• Fixation optimization: Different fixation methods (paraformaldehyde, methanol, acetone) can dramatically affect epitope accessibility. Systematically compare fixation methods to identify optimal protocols for consistent ERp57 detection.

• Antigen retrieval comparison: For tissue sections, compare heat-induced epitope retrieval methods (citrate buffer, EDTA, Tris) at various pH levels to determine optimal conditions for ERp57 epitope exposure.

• Antibody validation: Confirm antibody specificity using positive and negative controls, including ERp57 knockdown or knockout samples, to ensure that observed patterns reflect true ERp57 distribution.

• Blocking optimization: Test different blocking reagents (BSA, normal serum, commercial blockers) to reduce non-specific binding without compromising specific signal.

• Signal amplification: For weak signals, evaluate amplification systems (tyramide signal amplification, polymer-based detection) while monitoring background levels.

Detailed documentation of all optimization steps creates a robust protocol that yields consistent results across experiments and between researchers, essential for reproducible ERp57/PDIA3 studies.

What are the best practices for storage and handling to maintain ERp57/PDIA3 antibody performance?

Optimal storage and handling of ERp57/PDIA3 antibodies preserves their performance over time. Based on standard antibody handling protocols and specific information for ERp57 antibodies , researchers should implement these practices:

• Storage temperature: Store antibodies at -20°C to -70°C for long-term stability (up to 12 months from receipt date) . Avoid storing antibodies at 4°C for periods longer than one month.

• Aliquoting: Upon receipt, divide antibodies into small working aliquots to minimize freeze-thaw cycles. Each freeze-thaw cycle can reduce antibody activity.

• Freeze-thaw management: Use a manual defrost freezer and strictly avoid repeated freeze-thaw cycles . If thawing is necessary, thaw rapidly at room temperature and return to storage promptly.

• Reconstitution: For lyophilized antibodies, reconstitute according to manufacturer specifications, typically using sterile buffers. After reconstitution, antibodies can be stored at 2-8°C for one month or at -20 to -70°C for six months under sterile conditions .

• Contamination prevention: Use sterile technique when handling antibodies to prevent microbial contamination, which can degrade antibody performance.

• Transport conditions: When transferring antibodies between laboratories, maintain cold chain integrity using dry ice or specialized shipping containers.

Adherence to these practices maximizes antibody shelf-life and ensures consistent experimental results throughout the antibody's usable lifespan.

How should researchers compare results from different ERp57/PDIA3 antibody clones?

Comparing results obtained with different ERp57/PDIA3 antibody clones requires a systematic approach to account for their distinct properties:

• Epitope mapping: Determine the specific epitopes recognized by each antibody clone. Different domains of ERp57/PDIA3 may be preferentially exposed in various experimental conditions or biological states.

• Side-by-side validation: Test all antibody clones simultaneously on identical samples using consistent protocols to directly compare performance characteristics.

• Cross-validation with orthogonal methods: Confirm findings from antibody-based detection with orthogonal techniques such as mass spectrometry or RNA expression analysis.

• Isotype consideration: Account for differences in antibody isotypes (IgG, IgM) and host species, which may affect performance in certain applications or require different secondary detection reagents.

• Binding kinetics assessment: Evaluate association and dissociation rates of different antibody clones, as these properties influence detection sensitivity and washing stringency requirements.

• Reproducibility testing: Assess the reproducibility of results with each antibody clone across multiple experiments and between different researchers.

This comprehensive comparison approach enables researchers to select the most appropriate antibody clone for their specific application and interpret results accurately across studies using different ERp57/PDIA3 antibodies.

How might emerging antibody engineering techniques improve ERp57/PDIA3 antibody specificity and utility?

Emerging antibody engineering technologies offer promising approaches to enhance ERp57/PDIA3 antibody performance. Future developments may include:

• Single-domain antibodies: Engineering camelid-derived single-domain antibodies (nanobodies) against ERp57/PDIA3 could provide superior tissue penetration and recognition of cryptic epitopes inaccessible to conventional antibodies.

• Bi-specific antibodies: Developing antibodies that simultaneously target ERp57/PDIA3 and interaction partners could enable selective detection of functional protein complexes rather than total protein.

• Recombinant antibody fragments: Creating Fab or scFv fragments with optimized binding properties could improve performance in applications where full IgG molecules present steric hindrance.

• Affinity maturation: Applying in vitro evolution techniques to enhance antibody affinity and specificity for ERp57/PDIA3, particularly for distinguishing between closely related PDI family members.

• Site-specific conjugation: Engineering antibodies with site-specific attachment points for labels or functional groups could improve consistency in labeling density and orientation.

These advanced engineering approaches could transform ERp57/PDIA3 research by providing more precise tools for investigating specific forms, complexes, or modifications of this multifunctional protein.

What methodological advances are needed to better understand ERp57/PDIA3's role in protein folding and quality control?

Advancing our understanding of ERp57/PDIA3's functions in protein folding and quality control requires methodological innovations:

• Live-cell imaging probes: Development of non-interfering antibody-based probes or aptamers that can track ERp57/PDIA3 dynamics in living cells during protein folding and stress responses.

• Domain-specific inhibitors: Creation of inhibitors targeting specific functional domains of ERp57/PDIA3 would enable selective disruption of distinct activities (chaperone function versus enzymatic activity).

• Client-specific interaction assays: High-throughput methods to systematically identify and characterize ERp57/PDIA3 client proteins under various cellular conditions.

• Single-molecule analysis: Application of single-molecule techniques to directly observe ERp57/PDIA3-mediated protein folding events in real-time.

• Conditional knockout models: Development of tissue-specific or inducible ERp57/PDIA3 knockout systems to overcome the challenges of studying this essential protein in vivo.

• Structural biology integration: Combining antibody-based detection with structural techniques (cryoEM, X-ray crystallography) to capture ERp57/PDIA3 in different functional states.

These methodological advances would significantly enhance our ability to dissect the complex roles of ERp57/PDIA3 in cellular proteostasis and disease mechanisms.